Synuclein, alpha, Western Blot Positive Control control product blog
Tags: Control; Synuclein, alpha, Western Blot Positive Control; Synuclein, alpha, Western Blot Positive Control control;
The Synuclein, alpha, Western Blot Positive Control n/a (Catalog #MBS652638) is an Immunoglobulin and is intended for research purposes only. The product is available for immediate purchase. MyBioSource\'s Synuclein, alpha, Western Blot Positive Control can be used in a range of immunoassay formats including, but not limited to, Western Blot (WB).Suitable for use in Western Blot as a positive control.
Dilution: Western Blot: 10ul/lane. Researchers should empirically determine the suitability of the Synuclein, alpha, Western Blot Positive Control n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Parkinson\'s disease (PD) is a common neurodegenerative disorder with a lifetime incidence of approximately 2 percent; the clinical manifestations of this neurodegenerativedisorder include resting tremor, muscular rigidity, bradykinesia,and postural instability. A relatively specific pathological featureaccompanying the neuronal degeneration is an intracytoplasmicinclusion body, known as the Lewy body. A mutation was identified in the -synuclein gene, which codesfor a presynaptic protein thought to be involved in neuronal plasticity, this mutation may cause a conformational change that renders -synuclein more prone to self aggregation and deposition in Lewy bodies, which finally leads to oxidative stress and misfolding of -synuclein. Parkin gene, mutations in this gene are reported in early autosomal-recessive form of PD, however these mutations do not degenerate Lewy bodies. The Parkin gene product (Parkin) is involved in protein degradation as an ubiquitin protein ligase, the known substrates of Parkin include Pael-R (Parkin-associated endothelin receptor-like receptor), Ubiquitination of Pael-R by Parkin leads to its degradation in the proteasome, however failure to ubiquitinate it leads to death of neuron. The synuclein exists in 3 isoform -syn (chrm 4q21), a 140aa protein, implicated in pathogenesis of PD and related neurodegenerative disorders, it is mainly expressed in brain specifically in neuronal cell bodies and synapses. The 134 aa b-syn (chrm 5q35) is homologous to 14kD bovine phosphoneuroprotein 14; SCNB has been shown to be highly expressed in the substantia nigra of the brain. Recently a new isoform termed g-synuclein (SNCG) or breast cancer gene 1 (BCG1) has been cloned (human 127 aa (chrm 10q23), rat/mouse 123 aa). Higher levels of expression of SNCG has been reported in advanced breast carcinomas. All three synuclein show ~40% identity.